Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Journal of Southern Medical University ; (12): 432-434, 2012.
Artigo em Chinês | WPRIM | ID: wpr-267582

RESUMO

<p><b>OBJECTIVE</b>To analyze the clinical and laboratory characteristics of Gitelman syndrome.</p><p><b>METHODS</b>Seventeen patients with Gitelman syndrome (male/female: 11/6) were analyzed for their clinical symptoms, laboratory test results, imaging findings, treatments and outcomes.</p><p><b>RESULTS</b>Fifteen of the 17 patients presented with varying degrees of lower limb weakness, and 8 experienced flaccid paralysis. The laboratory tests showed hypokalemia (17/17), hypomagnesemia (17/17) and hypocalcemia (17/17). Blood renin activity (17/17), angiotensin II (14/17) and aldosterone levels (7/17) were significantly higher in the patients than in normal subjects. The symptoms were relieved by potassium alone or in combination with indomethacin, spironolactone and other potassium magnesium asparaginate, but the serum potassium and magnesium failed to recover the normal levels after the treatments.</p><p><b>CONCLUSION</b>The primary clinical manifestations of Gitelman syndrome are lower extremity weakness with hypokalemia and hypomagnesemia. Combined drug therapies including potassium, magnesium, aldosterone antagonists and other drugs are recommended. The prognosis of the patients is favorable.</p>


Assuntos
Adolescente , Adulto , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Síndrome de Gitelman , Diagnóstico , Tratamento Farmacológico , Indometacina , Usos Terapêuticos , Cloreto de Potássio , Usos Terapêuticos , Aspartato de Magnésio e Potássio , Usos Terapêuticos , Estudos Retrospectivos , Espironolactona , Usos Terapêuticos
2.
Journal of Huazhong University of Science and Technology (Medical Sciences) ; (6): 517-9, 2008.
Artigo em Inglês | WPRIM | ID: wpr-634938

RESUMO

The aim of this study was to determine if the potassium aspartate and magnesium (PAM) prevent reperfusion-induced ventricular arrhythmias (RIVA) in ischemia-reperfusion (IR) rabbit heart. Thirty rabbits were randomly divided into control, ischemia and PAM groups. Arterially-perfused rabbit left ventricular preparations were made, and transmural ECG as well as action potentials from both endocardium and epicardium were simultaneously recorded in the whole process of all experiments. In control group rabbit ventricular wedge preparations were continuously perfused with Tyrode's solution, and in ischemia group and PAM groups the perfusion of Tyrode's solution was stopped for 30 min. Then the ischemia group was reperfused with Tyrode's solution and the PAM group with Tyrode's solution containing 2.42 mg/L PAM, respectively. ECG, QT interval, transmural repolarization dispersion (TDR) and action potentials from epicardium and endocardium were simultaneously recorded, and the RIVA of the wedge preparation was observed. Compared with control group, TDR and incidence of RIVA were significantly increased in ischemia group (P<0.05). The incidence of RIVA in control, ischemia and PAM group was 0/10, 9/10 and 1/10, respectively. Compared with ischemia group, TDR and incidence of RIVA were significantly reduced in PAM group (P<0.05). Potassium aspartate and magnesium significantly reduce TDR and prevent ventricular arrhythmia in ischemic rabbit heart.


Assuntos
Arritmias Cardíacas/etiologia , Arritmias Cardíacas/prevenção & controle , Isquemia Miocárdica/complicações , Isquemia Miocárdica/fisiopatologia , Traumatismo por Reperfusão Miocárdica/complicações , Aspartato de Magnésio e Potássio/uso terapêutico , Distribuição Aleatória
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA